A Systematic Review of Infection Rates and Associated Antibiotic Duration in Acellular Dermal Matrix Breast Reconstruction

Brett T. Phillips, MD, MBA,a Muath Bishawi, MD, MPH,b Alexander B. Dagum, MD,c Duc T. Bui, MD,c and Sami U. Khan, MDc

aDivision of Plastic, Maxillofacial, & Oral Surgery and; bDivision of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, NC; and cDivision of Plastic and Reconstructive Surgery, Stony Brook University Hospital, Stony Brook University School of Medicine, Stony Brook, NY

Correspondence: brett.phillips@duke.edu

Keywords: breast reconstruction, acellular dermal matrix, ADM, infection, antibiotics

Introduction: Reported infection rates in breast reconstruction with acellular dermal matrix (ADM) can exceed 31%. Prophylactic antibiotics remain controversial due to the absence of evidence-based literature. The purpose of this study was to examine published antibiotic regimens and their associated infection rates in this population.

Methods: Systematic electronic searches were performed in PubMed, OVID, and the Cochrane databases for studies that reported on prophylactic antibiotic use and infection in patients undergoing ADM breast reconstruction. Two independent authors reviewed studies between 1970 and 2012 for inclusion and data extraction.

Results: A total of 863 studies were identified and abstracts reviewed. A total of 24 articles were included, with 2148 patients and 3189 ADM reconstructions. Mean infection rates varied between 0% and 31.25%, with a combined average of 11.59%. When comparing antibiotic protocols of less than 24 hours and more than 24 hours, the average infection rate was 2.48% and 13.21%, respectively.

Conclusion: The current literature lacks consensus on the necessary duration for postoperative antibiotic prophylaxis following breast reconstruction. The potential increased risk of infection associated with ADM remains controversial. Because of the lack of supportive evidence, we do not recommend prolonged postoperative antibiotics in ADM breast reconstruction.

Level of Evidence: Therapeutic level III evidence.

In 2013, more than 95,000 breast reconstructions were performed in the United States, with nearly 79% being tissue expander- and/or implant-based surgical procedures.1 It has been reported that up to 56% of these cases use acellular dermal matrix (ADM).2 In contrast to total submuscular coverage, ADM-assisted breast reconstruction has several reported benefits including additional lower pole implant coverage, allowing the possibility of direct

339
to implant reconstruction, increased tissue expander fill volumes at time of initial operation, and fewer expansions potentially decreasing the time to second-stage reconstruction. These potential benefits have been called into question in the recent literature, and new guidelines/protocols have been established to better define which patients are ideal candidates.

Although ADM reconstruction may provide significant benefits, extensive controversy exists as to whether ADM itself increases overall complication risks. Multiple systematic reviews and meta-analyses have perpetuated the controversy of whether ADM increases overall complications when used in breast reconstruction. Surgical site infection remains a significant complication, with overall breast reconstruction rates ranging from 0% to 29%, with an average of 5.8% in a recent systematic review. Infection rates in ADM reconstruction have a similar broad range between 0% and 31%. This is significantly higher than the expected surgical site infection rate of a clean elective operation as defined by the Centers for Disease Control and Prevention. The surgical placement of an implant under a nonvascularized dermal construct and poorly perfused mastectomy skin flaps has definite potential for increased complication rates. One non–evidence-based approach to this increased complication has been the use of postoperative antibiotics by up to 72% of surgeons. Prolonged antibiotics have been associated with systemic side effects, drug-resistant bacteria, and Clostridium difficile colitis and, in general, should not be used longer than 24 hours postoperatively. Many antibiotic protocols are described in the plastic surgery literature without a general consensus on terminology or duration, and frequently antibiotics are given longer than the recommended 24 hours. The purpose of this study was to perform a systematic review of the literature, examining the surgical site infection rates and associated antibiotic protocols in ADM-assisted breast reconstruction.

METHODS

Search methodology

Electronic searches were performed in PubMed, OVID, and the Cochrane databases for studies that reported on prophylactic antibiotic protocols for patients undergoing breast reconstruction with ADM and available infection rates. MeSH terms used in PubMed are as follows: (“Mammaplasty”[Mesh] AND “Anti-Bacterial Agents”[Mesh]), (“Acellular dermal matrix” AND Breast), (“Acellular dermal matrix” [Mesh] AND Breast), (“Acellular dermal matrix” [Mesh] AND “Anti-Bacterial Agents”[Mesh] AND Breast), (Breast reconstruction AND “Anti-Bacterial Agents”[Mesh]), (“Mammaplasty”[Mesh] AND antibiotics), (“Anti-Bacterial Agents”[Mesh] AND breast reconstruction AND “Infection”[Mesh] AND ADM), (breast reconstruction AND antibiotics), (“Infection”[Mesh] AND breast reconstruction), (“infection AND breast reconstruction). Similar terms were used in OVID. Studies in all languages, including international ones, written from January 1, 1970, to August 2012 were reviewed. References of included articles were also evaluated for further relevant studies for a full circular search.

Article selection criteria

Prior to data collection, a protocol was drafted and approved by the authors. This included the search criteria, article inclusion and exclusion criteria, and the decision not to contact
article authors for further missing information. To be included as part of this review, publications had to report on surgical outcomes of any form of breast reconstruction. All forms of first-stage implant-based breast reconstruction were included (tissue expander and/or implants). Furthermore, articles had to report on the use of ADM in at least one of the patients undergoing reconstruction. The use, or reporting of a specific antibiotic protocol as well as the rate of surgical site infection, was also required for article inclusion. Only retrospective and prospective studies were included; therefore, exclusion criteria included case reports, reviews, editorials, communications, correspondence, discussions, and letters. However, relevant articles that were not necessarily clinical studies were reviewed for relevant references.

Two independent reviewers (B.T.P., M.B.) performed the initial article search and subsequent selection. After duplicate deletion, each article abstract was reviewed for inclusion criteria. If the abstract did not meet clear inclusion or exclusion criteria, the full article was reviewed prior to final categorization.

Data collection and analysis

Data extraction was performed according to the Cochrane systematic review guidelines. The 2 reviewers extracted data from included articles and placed into an Excel database. Data collection included lead author, publication year, type of study, time range of study patients, type of reconstruction, type of ADM used, timing of reconstruction, total number of patients, total number of reconstructions, antibiotic protocol, and total number of infections. Rates of infection were based on the number of patients included in each study. Studies were further stratified into groups based on antibiotic protocol. Because of poorly defined antibiotic duration protocols, studies were categorized into groups based on the antibiotic regimen described within the article. These included preoperative/intraoperative antibiotics, 5 to 7 days of antibiotics, perioperative and/or antibiotics until drain removal, and nonspecific antibiotic protocol. Additional categorization placed studies into 2 groups: 24 hours or less of antibiotics and more than 24 hours of antibiotics. The number of patients, ADM use, and infections in each group were computed and infection rates were reported. The more than 24 hours of antibiotics group included all original groups besides the preoperative/intraoperative antibiotic studies.

RESULTS

Articles reviewed

Twenty-four articles met our inclusion criteria and were included in this review (Fig 1). Each included article with publication year, study dates, reconstruction type, antibiotic protocol, and infection rates are listed in Table 1. Article demographics are including in Table 2, with the majority of articles being retrospective reviews and only 3 prospective studies. Half of the studies included comparison data for patients undergoing non-ADM reconstructions, whereas the other half reported outcomes only for ADM patients. Multiple ADM types were used, with the majority using AlloDerm (92%) (Lifecell Corp, Branchburg, NJ), and most studies reported results for immediate reconstruction, with only 25% of studies containing patients with delayed reconstruction.
Antibiotic protocols

Similar to a previously published systematic review,\textsuperscript{15} approximately 7 different protocols were reported. The terminology “prophylactic antibiotics,” “postoperative antibiotics,” and “antibiotics until drain removal” were most commonly used and did not specify an exact antibiotic termination date. These articles encompassed two-thirds of our studies and were placed into a single group. For analysis, all protocols were placed into 1 of 4 groups (Table 3).

Infection rates

In the 24 included studies, we evaluated 2148 patients with 3189 ADM reconstructions. Using total patients as the denominator for analysis, we found an overall infection rate of 11.59%. When combining the comparative non-ADM patients within the included studies, we had 3357 patients with an overall infection rate that was less than half of the ADM patients at 4.74% (Table 4). When examining infection rates and associated antibiotic protocols, approximately 73% of patients were in the improperly defined perioperative/postoperative antibiotic regimen group, with an overall infection rate of 13.58% (Table 3). The highest infection rate was seen in the “no standard antibiotic protocol” group at 24.39%. This represented only a single study with only 2% of the total patients, although, overall, the highest ADM reconstruction infection was 31.25%.\textsuperscript{17} A different study\textsuperscript{41} was found to have the highest non-ADM reconstruction rate of 39.68%, with a combined ADM and non-ADM infection rate of 35.16% (Table 4).
| Author (Year)          | Study type and date range | Antibiotic protocol | Type of reconstruction | Types of ADM | # Patients | # Infections | % Infections |
|------------------------|---------------------------|---------------------|------------------------|--------------|------------|--------------|--------------|
| Breuing and Warren¹⁶ (2005) | Retrospective review, 2003 | Abx until drain removal | IBR (ADM)             | AlloDerm     | 10         | 0            | 0.00         |
| Salzberg²¹ (2006)      | Retrospective review, 2002–2006 | Intraoperative Abx  | IBR (ADM)             | AlloDerm     | 49         | 0            | 0.00         |
| Breuing and Colwill²² (2007) | Retrospective review, 2003–2005 | Abx until drain removal | IBR and DBR (ADM)     | AlloDerm     | 29         | 2            | 6.90         |
| Ashikari et al²³ (2008) | Retrospective review, 1988–2007 | Preoperative Abx   | IBR (ADM)             | AlloDerm     | 65         | 0            | 0.00         |
| Spear et al²⁴ (2008)   | Prospective study, 2004–2005 | Abx until drain removal | IBR (ADM)             | AlloDerm     | 43         | 4            | 9.30         |
| Topol et al²⁵ (2008)   | Retrospective review, 2006–2007 | Preoperative Abx   | IBR (ADM)             | AlloDerm/FlexHD | 23         | 2            | 8.70         |
| Murray et al²⁶ (2009)  | Retrospective review, 2003–2008 | Abx until drain removal | IBR (ADM)             | AlloDerm     | 18         | 0            | 0.00         |
| Nahabedian²⁷ (2009)    | Retrospective review, 1997–2008 | Abx until drain removal | IBR (non-ADM)         | None         | 121        | 10           | 8.26         |
| Naumann²⁸ (2009)       | Prospective study, 2006–2007 | Abx until drain removal | IBR (ADM)             | AlloDerm     | 76         | 5            | 6.58         |
| Sbitany et al²⁹ (2009) | Retrospective review, 2004–2007 | 5 d of postoperative Abx | IBR (ADM)             | AlloDerm     | 50         | 8            | 16.00        |
| Antony et al³⁰ (2010)  | Retrospective review, 2004–2008 | 5 d of postoperative Abx | IBR (non-ADM)         | None         | 285        | 22           | 7.72         |
| Chun et al³¹ (2010)    | Retrospective review, 2002–2008 | Abx until drain removal | IBR (non-ADM)         | None         | 96         | 11           | 11.46        |
| Lanier et al³² (2010)  | Retrospective review, 2005–2008 | Abx until drain removal | IBR and DBR (ADM)     | AlloDerm/FlexHD | 2025       | 38           | 1.88         |

**Table 1. Systematic review study list**
| Author (Year)          | Study type and date range | Antibiotic protocol                          | Type of reconstruction | Types of ADM | # Patients | # Infections | % Infections |
|------------------------|---------------------------|----------------------------------------------|------------------------|--------------|------------|--------------|--------------|
| Nguyen et al32 (2010)  | Retrospective review, 1998–2008 | Nonspecific Abx protocol | IBR and DBR (ADM)     | AlloDerm     | 41         | 10           | 24.39        |
|                        |                           | Nonspecific Abx protocol | IBR and DBR (non-ADM) | None         | 163        | 11           | 6.75         |
| Liu et al33 (2011)     | Retrospective review, 2004–2009 | Abx until drain removal | IBR (ADM)            | AlloDerm     | 192        | 18           | 9.38         |
| Rawlani et al34 (2011) | Retrospective review, 2009  | Abx until drain removal | IBR (non-ADM)        | None         | 151        | 5            | 3.31         |
|                        |                           | Perioperative Abx       | IBR (ADM)            | FlexHD       | 84         | 9            | 10.71        |
| Cassileth et al35 (2012)| Retrospective review, 2005–2010 | Abx until drain removal | IBR (ADM)            | AlloDerm     | 43         | 5            | 11.63        |
| Chepla et al36 (2012)  | Retrospective review, 2007–2010 | 5 d of postoperative Abx | IBR and DBR (ADM)    | AlloDerm     | 145        | 9            | 6.21         |
| Endress et al37 (2012) | Retrospective review, 2006–2010 | 7 d of postoperative Abx | IBR (ADM)            | Surgimend    | 28         | 2            | 7.14         |
| Glasberg and Light38   (2012) | Retrospective review, 2004–2011 | 7 d of postoperative Abx | IBR (non-ADM)        | None         | 91         | 9            | 9.89         |
|                        |                           | Preoperative Abx        | IBR (ADM)            | AlloDerm/Strattice | 186     | 6            | 3.23         |
| Leyngold et al39 (2012)| Retrospective review, 2006–2008 | Abx until drain removal | IBR and DBR (ADM)    | AlloDerm     | 86         | 7            | 8.14         |
| Spear et al40 (2012)   | Retrospective review, 2004–2010 | Abx until drain removal | IBR and DBR (non-ADM)| None         | 109        | 3            | 2.75         |
|                        |                           | Abx until drain removal | IBR (ADM)            | AlloDerm     | 289        | 23           | 7.96         |
| Peled et al41 (2012)   | Prospective study, 2006–2010 | Abx until drain removal | IBR (ADM)            | AlloDerm     | 65         | 20           | 30.77        |
| Weichman et al42 (2012)| Retrospective review, 2007–2010 | Abx until drain removal | IBR (non-ADM)        | None         | 63         | 25           | 39.68        |
|                        |                           | Abx until drain removal | IBR (ADM)            | AlloDerm     | 286        | 68           | 23.78        |

IBR indicates immediate breast reconstruction; DBR, delayed breast reconstruction; ADM, acellular dermal matrix; Abx, antibiotics.
**Table 2. Article demographics**

| Article demographics | n | %  |
|----------------------|---|----|
| Study design         |   |    |
| Randomized controlled trial | 0 | 0.0 |
| Prospective study    | 3 | 12.5|
| Retrospective review | 21| 87.5|
| Study type           |   |    |
| ADM only             | 12| 50.0|
| ADM and non-ADM      | 12| 50.0|
| Breast reconstruction timing |   |    |
| Immediate only       | 18| 75.0|
| Immediate and delayed| 6 | 25.0|
| ADM type             |   |    |
| AlloDerm             | 19| 79.2|
| AlloDerm and FlexHD/Strattice | 3 | 12.5|
| FlexHD               | 1 | 4.2 |
| Surgimend            | 1 | 4.2 |

ADM indicates acellular dermal matrix.

**Table 3. Antibiotic protocol with ADM infection rates**

| Antibiotic Protocol                               | # Studies | # Patients | # Infections | Mean infection rate | Infection rate range     |
|---------------------------------------------------|-----------|------------|--------------|---------------------|--------------------------|
| Preoperative/intraoperative antibiotics            | 4         | 323        | 8            | 2.48%               | 0%–8.70%                 |
| 5–7 days of antibiotics                            | 3         | 223        | 19           | 8.52%               | 6.21%–16.00%             |
| Perioperative and antibiotics until drain removal  | 16        | 1561       | 212          | 13.58%              | 6.21%–16.00%             |
| Nonspecific antibiotic protocol                    | 1         | 41         | 10           | 24.39%              | 24.39%                   |
| Total                                              | 24        | 2148       | 249          | 11.59%              | 0%–31.25%                |

ADM indicates acellular dermal matrix.

**Table 4. ADM versus non-ADM comparative infection rates**

| Type of reconstruction | Studies, (n) | Patient, (n) | Recon, (n) | Infection rate (P) | Infection rate (R) | Infection rate range (P) | Infection rate range (R) |
|------------------------|--------------|--------------|------------|-------------------|-------------------|--------------------------|--------------------------|
| ADM                    | 24           | 2148         | 3189       | 249               | 250               | 11.59%                   | 7.84%                    | 0%–31.25%                |
| Non-ADM                | 12           | 3357         | 4791       | 159               | 159               | 4.74%                    | 3.32%                    | 1.88%–39.68%             |
| Total                  | 24           | 5505         | 7980       | 408               | 409               | 7.41%                    | 5.13%                    | 0%–35.16%                |

ADM indicates acellular dermal matrix; n, number; P, patient; R or Recon, reconstruction.

The overall combined ADM and non-ADM infection rate of 5505 patients was 7.41%. We further stratified our study results to examine the effect of reconstruction timing on infection (Table 5). Rates of infection in ADM patients were increased regardless of whether the study contained immediate or delayed reconstructions. Studies containing patients with delayed ADM reconstruction had similar infection rates to studies with immediate ADM reconstructions (11.29% vs 11.67%). Of interest, patients with delayed non-ADM reconstructions had a higher infection rate than those with immediate non-ADM reconstructions.
Unfortunately, because of reporting limitations of the original studies, it was difficult to determine the exact cause for this increase, although delayed reconstruction may have a higher infection rate due to postoperative chemotherapy and/or radiation.

### Table 5. Reconstruction timing and infection rates

| Study type               | # Patients | # Infections | Infection rate |
|-------------------------|------------|--------------|----------------|
| ADM                     | 2148       | 249          | 11.59%         |
| Non-ADM                 | 3357       | 159          | 4.74%          |
| IBR ADM only            | 1723       | 201          | 11.67%         |
| IBR non-ADM only        | 2729       | 114          | 4.18%          |
| IBR total               | 4452       | 315          | 7.08%          |
| IBR and DBR ADM only    | 425        | 48           | 11.29%         |
| IBR and DBR non-ADM only| 628        | 45           | 7.17%          |
| IBR and DBR total       | 1053       | 93           | 8.83%          |
| Total                   | 5505       | 408          | 7.41%          |

IBR indicates immediate breast reconstruction; DBR, delayed breast reconstruction; ADM, acellular dermal matrix.

In addition, we condensed our studies into antibiotic protocols of less than or more than 24 hours to evaluate infection rates of studies that followed the Centers for Disease Control and Prevention recommendations (Table 6). A majority of studies (83%) used prolonged duration of antibiotics of more than 24 hours, with an average infection of 13.21%. Studies that used less than 24 hours of antibiotics had one-fifth the infection rate at 2.48%.

### Table 6. Antibiotic protocol with ADM infection rates (< or > 24 hours)

| Abx protocol | # Studies | # Patients | # Infections | Mean infection rate | Infection rate range |
|--------------|-----------|------------|--------------|---------------------|---------------------|
| <24 hours    | 4         | 323        | 8            | 2.48%               | 0%–8.70%            |
| >24 hours    | 20        | 1825       | 241          | 13.21%              | 0%–31.25%           |
| Total        | 24        | 2148       | 249          | 11.59%              | 0%–31.25%           |

Abx indicates antibiotics.

**DISCUSSION**

The reported complication risks of ADM-associated, implant-based breast reconstructions remain controversial, with studies reporting conflicting complication rates. Four of the 12 comparative studies in our review reported decreased infection rates when using ADM, whereas the rest still cite increased infections. The average infection rate associated with ADM reconstruction was 11.59% compared with the non-ADM patients at 4.74%. Interestingly, the highest infection rate (39.68%) was discovered in a cohort of non-ADM patients. We found a wide range of infection rates in patients undergoing breast reconstruction with and without ADM that remain consistent with the recent literature. We also found that definitions of infections varied across all of our studies, and most did not use the standard surgical site infection grading scale. Some studies reported infections using the descriptions “minor” and “major,” which are very
subjective and not universally defined. Other studies reported only on infections requiring hospital readmission and/or implant loss. Patients with a diagnosis of cellulitis and treated with oral antibiotics were often excluded. Because of these limitations and the retrospective nature of these articles, it is also likely that the actual infection rates are underreported.

In addition to our review, we examined 10 recent meta-analyses and systematic reviews that provided pooled complication rates and various statistical methods to determine complication rates in patients undergoing ADM breast reconstruction. Adetayo et al\textsuperscript{14} and Newman et al\textsuperscript{11} examined ADM breast reconstruction complications without comparison data and showed infection rates of 9.5\% and 5.6\%, respectively. Newman et al\textsuperscript{11} reported a 12\% overall short-term complication rate associated with ADM. Looking specifically at infection, Jansen and Macadam\textsuperscript{12} found that infection rates ranged from 0\% to 11\% and noted that a true meta-analysis was difficult due to the lack of validated or standardized outcome measures in the included studies. Three additional meta-analyses compared submuscular coverage versus ADM breast reconstruction and found a 2- to 3-fold increased risk of infection with ADM along with 3- to 4-fold increase in seromas.\textsuperscript{8,9,13} Sbitany and Serletti\textsuperscript{10} performed a similar analysis and found a significant increase in seromas but not infections. Combined infection rates in these studies ranged from 4\% to 7\% in both submuscular and ADM reconstructions, similar to our combined infection rate of 5.13\%. These reported infection rates all used the number of reconstructions as the denominator instead of patients. We provided both percentages in our study and believe that studies reporting infection rates should provide both rates to get a better picture of the true infection risk. Our group previously suggested the appropriate unit of analyses when reporting complication rates in a preceding article.\textsuperscript{15} Ho et al\textsuperscript{9} also cited the difficulty in performing combined analysis due to nonuniform definitions of outcome measures. They also recommended the use of a “defined postoperative course of prophylactic antibiotic therapy,” which was infrequently provided or described appropriately.\textsuperscript{9}

The most recent and largest reviews have used surgical databases such as National Surgical Quality Improvement Project (NSQIP) and Tracking Operations and Outcomes for Plastic Surgeons (TOPS). Davila et al\textsuperscript{7} reported a 3.8\% versus 3.3\% infection rate in patients undergoing ADM breast reconstruction and submuscular coverage, respectively. Ibrahim et al\textsuperscript{45} found that superficial surgical site infections were significantly higher in ADM patients at 2.1\% than in patients without ADM at 1.6\% . Pannucci et al\textsuperscript{44} used the TOPS database and found ADM to be associated with a significant increase in expander or implant loss with an odds ratio of 1.42. These database articles include only short-term complications that are reported up to 30 days. This hardly gives us the true incidence of postoperative complications, especially with respect to infection. According to the Centers for Disease Control and Prevention, implant-based procedures require documentation of surgical site infection up to 1 year after the operation.\textsuperscript{18} One benefit, in contrast to the other meta-analyses in our literature, is that NSQIP data report infection using patient number as the denominator rather than reconstruction.

Since the completion of our review, additional publications in the plastic surgery literature have continued to show increased infection rates in patients undergoing ADM breast reconstruction. Brooke et al\textsuperscript{45} found patients undergoing ADM reconstructions to have infection rates 5 times higher than patients with non-ADM reconstructions with almost 2 times higher overall complications. Liu et al\textsuperscript{46} found a 10.7\% infection rate in patients
undergoing ADM reconstruction compared with 7.3% in patients undergoing without ADM reconstruction. Although not a primary outcome, McCarthy et al 3 in a multicenter randomized controlled trial found an infection rate of 8.3% and 3.0% in ADM and submuscular reconstructions, respectively. Overall complication rates were similar between groups. None of these studies reported their respective antibiotic protocols in their methodology. In an effort to decrease overall complication risks, Ganske et al 5 reported a study with modified postoperative care guidelines to decrease seroma rates. These modifications included postoperative uniform compressive dressings with a surgical bra and removing drains at 20 mL per 24 hours instead of 30 mL per 24 hours. The overall ADM-associated infection rate decreased from 7% to 3.8% following this protocol change. The most significant reduction was observed with major infections, which decreased from 7% to 1.9%. These patients received postoperative antibiotics until drains were removed, with a mean time to removal of 15 days.

In this systematic review, we included 24 articles with at least 7 different antibiotic regimens. The majority of studies were placed into a vague postoperative group. This group had the largest patient size and the second highest average infection rate at 13.58%, with 1 study reporting at 31.25%. 17 Patients who were reported to obtain more than 24 hours of antibiotics had 5.3 times higher infection rates. In a previous systematic review of almost 15,000 patients undergoing breast reconstruction, we found no difference between patients receiving less than or more than 24 hours of postoperative antibiotics (5.76% vs 5.78%). 15 Although several limitations can be considered when examining both of these systematic reviews, one can concede that prolonged antibiotics do not appear to decrease infection rates. Higher level evidence is needed to support this continued practice.

Although evidence-based use of appropriate postoperative antibiotics has become a hot topic in the surgical literature, there are few articles addressing this specific issue in breast reconstruction. Clayton et al 47 compared a prospective cohort of patients receiving only a single preoperative dose of antibiotics with a retrospective group of patients who received antibiotics until drain removal. They found a 4.7-fold increase in surgical site infections, with implant loss in the single preoperative dose group. Their overall reported surgical site infection rate was 27%, with 18% infection rate in the group with antibiotics until drain removal. They concluded that a single dose of antibiotics was not sufficient and that an optimal course of antibiotics is still unknown. Avashia et al 48 published a retrospective study that examined different antibiotic regimens in patients undergoing ADM breast reconstruction performed by a single surgeon. A series of 12 patients (19 breasts) were given less than 24 hours of perioperative antibiotics and compared with a previous and subsequent cohort of patients who received more than 48 hours of antibiotics. Six of the 12 patients in the less than 24 hours of antibiotics group required implant removal due to infection (6/19 reconstructions). This was significantly higher than the incidence in the other cohorts, 7.9% and 3.2%, respectively. This article claims that administration of 24 hours of antibiotics is clearly not enough for postoperative prophylaxis, basing it upon a comparison of only 12 patients over a 1-month period. Another study by Liu et al 49 although examining autologous breast reconstruction, showed no difference in infection rates between patients who received less than or more than 24 hours of antibiotics (19.5% vs 15.5%).

A recent abstract presented by our group provided preliminary results of a randomized controlled trial of patients undergoing ADM breast reconstruction and antibiotic duration. 50
Patients were randomized to receive 24 hours of perioperative antibiotics versus antibiotics until drain removal. In more than 100 patients, no significant difference was identified in overall infection rates between the 2 groups (15.4% vs 12.2%, respectively). In fact, the 24-hour group had more superficial surgical site infections whereas the latter group had increased implant loss secondary to infection. Final results of this study are subject to a future analysis. It is hoped that this study will be a step toward providing sufficient evidence-based recommendations for postoperative antibiotic prophylaxis in breast reconstruction. Additional large-volume and multicentered trials would assist in answering this question.

There are several limitations of this study that must be considered when interpreting our results. These limitations stem directly from the limitations of the reviewed literature. Specifically, many of the studies suffered from reporting and recall bias, as well as lack of reporting on specifics of their clinical outcomes measures. We excluded studies that specifically looked at infection rates in patients undergoing ADM breast reconstruction because they neglected to mention an antibiotic regimen, which may have impacted our conclusions. Because most of these included studies were retrospective in nature, recall of the antibiotic regimen may not have been completely accurate. Studies stating that preoperative antibiotics were given without mention of postoperative antibiotics might have actually received a postoperative course. In addition, patients were not mutually exclusive and there is a possibility that patients were duplicated in studies. It is common in our field to publish larger series as our sample size increases. As stated previously, the unit of analysis in which our outcomes are reported can significantly change the complication rates. Most articles described infection rates as a function of reconstructions rather than patients. In addition, definitions of infection and antibiotic regimens were not universal across studies. It was also difficult to completely separate patients with immediate and delayed breast reconstruction to accurately assess a difference in outcomes. For the aforementioned reasons, a complete and accurate meta-analysis was impossible. Phillips et al\textsuperscript{15} discussed these inherent literature-reporting drawbacks evident in another systematic review examining a similar question in all forms of breast reconstruction. A uniform breast reconstruction surgical site infection grading scale was provided in addition to recommendations on reporting units of analysis for outcome-based research.

**CONCLUSION**

Breast reconstruction is associated with a high infection and overall complication rate. Patients are frequently managed with postoperative antibiotics, although the current literature lacks consensus on the necessary duration following ADM breast reconstruction. The potential increased risk of infection associated with ADM remains controversial, with deficient high-level evidence supporting the necessity for postoperative antibiotics. This study found that ADM reconstruction was associated with a higher infection rate than that reported in patients with non-ADM reconstruction. Interestingly, the lowest rate of infections was seen in patients who received less than 24 hours of antibiotics. Regardless of the type of breast reconstruction, we cannot support the unsubstantiated use of antibiotics past the 24-hour perioperative period in patients with ADM or non-ADM breast reconstruction.
REFERENCES

1. American Society of Plastic Surgeons. 2013 Plastic Surgery Statistics Report. Arlington Heights, Ill: American Society of Plastic Surgeons; 2014;9.

2. JoAnna Nguyen T, Carey JN, Wong AK. Use of human acellular dermal matrix in implant-based breast reconstruction: evaluating the evidence. J Plast Reconstr Aesthet Surg. 2011;64(12):1553-61.

3. McCarthy CM, Lee CN, Halvorson EG, et al. The use of acellular dermal matrices in two-stage expander/implant reconstruction: a multicenter, blinded, randomized controlled trial. Plast Reconstr Surg. 2012;130(5, suppl 2):57S-66S.

4. Martin L, O’Donoghue JM, Horgan K, et al. Acellular dermal matrix (ADM) assisted breast reconstruction procedures: joint guidelines from the Association of Breast Surgery and the British Association of Plastic, Reconstructive and Aesthetic Surgeons. Eur J Surg Oncol. 2013;39(5):425-9.

5. Ganske I, Verma K, Rosen H, Eriksson E, Chun YS. Minimizing complications with the use of acellular dermal matrix for immediate implant-based breast reconstruction. Ann Plast Surg. 2013;71(5):464-70.

6. Jansen LA, De Caigny P, Guay NA, Lineaweaver WC, Shokrollahi K, et al. The evidence base for the acellular dermal matrix AlloDerm: a systematic review. Ann Plast Surg. 2013;70(5):587-94.

7. Davila AA, Seth AK, Wang E, et al. Human acellular dermis versus submuscular tissue expander breast reconstruction: a multivariate analysis of short-term complications. Arch Plast Surg. 2013;40(1):19-27.

8. Kim JY, Davila AA, Persing S, et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plast Reconstr Surg. 2012;129(1):28-41.

9. Ho G, Nguyen TJ, Shahabi A, Hwang BH, Chan LS, Wong AK. A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction. Ann Plast Surg. 2012;68(4):346-56.

10. Sbitany H, Serletti JM. Acellular dermis-assisted prosthetic breast reconstruction: a systematic and critical review of efficacy and associated morbidity. Plast Reconstr Surg. 2011;128(6):1162-9.

11. Newman MI, Swartz KA, Samson MC, Mahoney CB, Diab K. The true incidence of near-term postoperative complications in prosthetic breast reconstruction utilizing human acellular dermal matrices: a meta-analysis. Aesthetic Plast Surg. 2011;35(1):100-6.

12. Jansen LA, Macadam SA. The use of AlloDerm in postmastectomy alloplastic breast reconstruction, part I: a systematic review. Plast Reconstr Surg. 2011;127(6):2232-44.

13. Hoppe IC, Yueh JH, Wei CH, Ahuja NK, Patel PP, Datiashvili RO. Complications following expander/implant breast reconstruction utilizing acellular dermal matrix: a systematic review and meta-analysis. Eplasty. 2011;11:e40.

14. Adetayo OA, Salcedo SE, Bahjri K, Gupta SC. A meta-analysis of outcomes using acellular dermal matrix in breast and abdominal wall reconstructions: event rates and risk factors predictive of complications [published online ahead of print December 9, 2011]. Ann Plast Surg. doi:10.1097/SAP.0b013e31822afae5.

15. Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence?. Plast Reconstr Surg. 2013;131(1):1-13.

16. Breuing KH, Warren SM. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. Ann Plast Surg. 2005;55(3):232-9.

17. Lanier ST, Wang ED, Chen JJ, et al. The effect of acellular dermal matrix use on complication rates in tissue expander/implant breast reconstruction. Ann Plast Surg. 2010;64(5):674-8.

18. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27(2):97-132, quiz 133-4; discussion 96.

19. Phillips BT, Wang ED, Mirrer J, et al. Current practice among plastic surgeons of antibiotic prophylaxis and closed-suction drains in breast reconstruction: experience, evidence, and implications for postoperative care. Ann Plast Surg. 2011;66(5):460-5.

20. Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt). 2008;9(6):579-84.

21. Salzberg CA. Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm). Ann Plast Surg. 2006;57(1):1-5.

22. Breuing KH, Colwell AS. Inferolateral AlloDerm hammock for implant coverage in breast reconstruction. Ann Plast Surg. 2007;59(3):250-5.
23. Ashikari RH, Ashikari AY, Kelemen PR, Salzberg CA. Subcutaneous mastectomy and immediate reconstruction for prevention of breast cancer for high-risk patients. *Breast Cancer*. 2008;15(3):185-91.
24. Spear SL, Parikh PM, Resin E, Menon NG. Acellular dermis-assisted breast reconstruction. *Aesthetic Plast Surg*. 2008;32(3):418-25.
25. Topol BM, Dalton EF, Ponn T, Campbell CJ. Immediate single-stage breast reconstruction using implants and human acellular dermal tissue matrix with adjustment of the lower pole of the breast to reduce unwanted lift. *Ann Plast Surg*. 2008;61(5):494-9.
26. Murray JD, Elwood ET, Jones GE, Barrick R, Feng J. Decreasing expander breast infection: a new drain care protocol. *Can J Plast Surg*. 2009;17(1):17-21.
27. Nahabedian MY. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. *Plast Reconstr Surg*. 2009;124(6):1743-53.
28. Namnoum JD. Expander/implant reconstruction with AlloDerm: recent experience. *Plast Reconstr Surg*. 2009;124(2):387-94.
29. Sbitany H, Sandeen SN, Amalfi AN, Davenport MS, Langstein HN. Acellular dermis-assisted prosthetic breast reconstruction versus complete submuscular coverage: a head-to-head comparison of outcomes. *Plast Reconstr Surg*. 2009;124(6):1735-40.
30. Antony AK, McCarthy CM, Cordeiro PG, et al. Acellular human dermis implantation in 153 immediate two-stage tissue expander breast reconstructions: determining the incidence and significant predictors of complications. *Plast Reconstr Surg*. 2010;125(6):1606-14.
31. Chun YS, Verma K, Rosen H, et al. Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications. *Plast Reconstr Surg*. 2010;125(2):429-36.
32. Nguyen MD, Chen C, Colakoglu S, Morris DJ, Tobias AM, Lee BT. Infectious complications leading to explantation in implant-based breast reconstruction with AlloDerm. *Eplasty*. 2010;10:e48.
33. Liu AS, Kao HK, Reish RG, Hergrueter CA, May JW Jr, Guo L. Postoperative complications in prosthesis-based breast reconstruction using acellular dermal matrix. *Plast Reconstr Surg*. 2011;127(5):1755-62.
34. Rawlani V, Buck DW 2nd, Johnson SA, Heyer KS, Kim JY. Tissue expander breast reconstruction using prehydrated human acellular dermis. *Ann Plast Surg*. 2011;66(6):593-7.
35. Cassileth L, Kohanzadeh S, Amersi F. One-stage immediate breast reconstruction with implants: a new option for immediate reconstruction. *Ann Plast Surg*. 2012;69(2):134-8.
36. Cheplak KJ, Dagget JR, Soltanian HT. The partial AlloDerm sling: reducing allograft costs associated with breast reconstruction. *J Plast Reconstr Aesthet Surg*. 2012;65(7):924-30.
37. Endress R, Choi MS, Lee GK. Use of fetal bovine acellular dermal xenograft with tissue expansion for staged breast reconstruction. *Ann Plast Surg*. 2012;68(4):338-41.
38. Glasberg SB, Light D. AlloDerm and Strattice in breast reconstruction: a comparison and techniques for optimizing outcomes. *Plast Reconstr Surg*. 2012;129(6):1223-33.
39. Leyngold MM, Stutman RL, Khiabani KT, et al. Contributing variables to post mastectomy tissue expander infection. *Breast J*. 2012;18(2):351-6.
40. Spear SL, Seruya M, Rao SS, et al. Two-stage prosthetic breast reconstruction using AlloDerm including outcomes of different timings of radiotherapy. *Plast Reconstr Surg*. 2012;130(1):1-9.
41. Peled AW, Foster RD, Garwood ER, et al. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. *Plast Reconstr Surg*. 2012;129(6):901e-8e.
42. Weichman KE, Wilson SC, Weinstein AL, et al. The use of acellular dermal matrix in immediate two-stage tissue expander breast reconstruction. *Plast Reconstr Surg*. 2012;129(5):1049-58.
43. Ibrahim AM, Shuster M, Koolen PG, et al. Analysis of the National Surgical Quality Improvement Program database in 19,100 patients undergoing implant-based breast reconstruction: complication rates with acellular dermal matrix. *Plast Reconstr Surg*. 2013;132(5):1057-66.
44. Pannucci CJ, Antony AK, Wilkins EG. The impact of acellular dermal matrix on tissue expander/implant loss in breast reconstruction: an analysis of the tracking outcomes and operations in plastic surgery database. *Plast Reconstr Surg*. 2013;132(1):1-10.
45. Brooke S, Mesa J, Uluer M, et al. Complications in tissue expander breast reconstruction: a comparison of AlloDerm, DermaMatrix, and FlexHD acellular inferior pole dermal slings. *Ann Plast Surg*. 2012;69(4):347-9.
46. Liu DZ, Mathes DW, Neligan PC, Said HK, Louie O. Comparison of outcomes using AlloDerm versus FlexHD for implant-based breast reconstruction. Ann Plast Surg. 2014;72(5):503-7.
47. Clayton JL, Bazakas A, Lee CN, Hultman CS, Halvorson EG. Once is not enough: withholding postoperative prophylactic antibiotics in prosthetic breast reconstruction is associated with an increased risk of infection. Plast Reconstr Surg. 2012;130(3):495-502.
48. Avashia YJ, Mohan R, Berhane C, Oeltjen JC. Postoperative antibiotic prophylaxis for implant-based breast reconstruction with acellular dermal matrix. Plast Reconstr Surg. 2013;131(3):453-61.
49. Liu DZ, Dubbins JA, Louie O, Said HK, Neligan PC, Mathes DW. Duration of antibiotics after microsurgical breast reconstruction does not change surgical infection rate. Plast Reconstr Surg. 2012;129(2):362-7.
50. Phillips BT, Fourman MS, Dagum AB. Results of a prospective randomized clinical trial assessing postoperative antibiotic use in immediate breast reconstruction. J Am Coll Surg. 2013;217(3, suppl):S88.